Financial Survey: Traws Pharma (TRAW) versus Its Rivals

Traws Pharma (NASDAQ:TRAW) is one of 458 public companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Traws Pharma to similar businesses based on the strength of its institutional ownership, valuation, analyst recommendations, earnings, risk, dividends and profitability.

Insider and Institutional Ownership

7.9% of Traws Pharma shares are held by institutional investors. Comparatively, 31.4% of shares of all “Biotechnology” companies are held by institutional investors. 3.3% of Traws Pharma shares are held by insiders. Comparatively, 22.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Traws Pharma and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Traws Pharma	-60,641.14%	-144.95%	-633.17%
Traws Pharma Competitors	-8,998.21%	-106.36%	-31.08%

Analyst Ratings

This is a summary of recent recommendations for Traws Pharma and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	0	0	0	0	N/A
Traws Pharma Competitors	809	2390	6001	68	2.57

As a group, “Biotechnology” companies have a potential upside of 21.20%. Given Traws Pharma’s peers higher possible upside, analysts clearly believe Traws Pharma has less favorable growth aspects than its peers.

Valuation & Earnings

This table compares Traws Pharma and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Traws Pharma	$226,000.00	-$18.95 million	-8.62
Traws Pharma Competitors	$147.17 million	-$19.01 million	107.43

Traws Pharma’s peers have higher revenue, but lower earnings than Traws Pharma. Traws Pharma is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Traws Pharma has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500. Comparatively, Traws Pharma’s peers have a beta of 1.24, meaning that their average stock price is 24% more volatile than the S&P 500.

Summary

Traws Pharma peers beat Traws Pharma on 8 of the 10 factors compared.

About Traws Pharma

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.